| Therapy | Class / mechanism | Main indication in neurofibroma | Key clinical results | FDA approval status | Notable adverse effects / limitations |
|---|---|---|---|---|---|
| Selumetinib | MEK1/2 inhibitor; suppresses RAF-MEK-ERK signaling downstream of NF1 loss | Symptomatic, inoperable NF1-associated plexiform neurofibromas (PN), primarily pediatric | Phase II: 68% confirmed partial response (34/50), median best tumor volume reduction 27.9%; Phase I/II long-term follow-up: 70% overall confirmed partial response with durable pain improvement; systematic review cites ~68-71% partial response (pqac-00000024, pqac-00000021, pqac-00000025, pqac-00000028) | FDA approved in 2020 for pediatric patients with symptomatic, inoperable NF1-PN; also supported by approval-linked Open Targets evidence for MAP2K1/MAP2K2 (pqac-00000021, pqac-00000024, pqac-00000000) | Rash, vomiting, diarrhea, nausea, fatigue; grade 3 adverse events reported; cardiomyopathy and ocular toxicity require monitoring; prolonged therapy often needed because tumors may regrow after discontinuation (pqac-00000027, pqac-00000028) |
| Mirdametinib | MEK inhibitor | NF1-associated plexiform neurofibromas, including symptomatic/inoperable disease | Partial response reported in 42-50% of patients, with improvements in pain and functioning in trial summaries/reviews (pqac-00000022, pqac-00000023, pqac-00000025) | FDA approved in 2024 for NF1 with symptomatic plexiform neurofibromas according to current treatment reviews and user-specified latest landscape; active studies ongoing (pqac-00000022, pqac-00000023) | Acneiform rash very common (~94.7% in one study summary), nausea, diarrhea; some patients required dose reductions; class toxicities similar to other MEK inhibitors (pqac-00000022, pqac-00000023) |
| Trametinib | MEK inhibitor | Investigational treatment for NF1-associated plexiform neurofibromas, including pediatric populations | Studied in children aged 1-17 years; efficacy signal noted in reviews, but no pivotal response rate as established as selumetinib in the cited evidence (pqac-00000022, pqac-00000024) | Not FDA approved specifically for neurofibroma / NF1-PN in cited evidence | Dermatologic and gastrointestinal class toxicities expected; long-term comparative efficacy remains uncertain (pqac-00000022, pqac-00000026) |
| Binimetinib | MEK inhibitor | Investigational therapy for NF1-associated plexiform neurofibromas | Included in ongoing/previous clinical development programs for NF1-PN; no definitive response rate provided in the gathered evidence excerpt (pqac-00000021, pqac-00000024) | Not FDA approved specifically for neurofibroma / NF1-PN in cited evidence | MEK inhibitor class toxicities likely, including rash and gastrointestinal events; evidence still emerging (pqac-00000021, pqac-00000026) |
| Cabozantinib | Multikinase tyrosine kinase inhibitor | Unresectable, progressive, or symptomatic NF1-associated plexiform neurofibromas, especially adolescents/adults | Partial response in 42% of patients; associated with pain reduction in reported studies/reviews (pqac-00000022, pqac-00000023, pqac-00000025) | Not FDA approved specifically for neurofibroma / NF1-PN in cited evidence | Fatigue, gastrointestinal effects, hypothyroidism, dermatologic toxicities; used investigationally (pqac-00000022) |
| NFX-179 topical gel | Topical, metabolically labile MEK inhibitor | Cutaneous neurofibromas (cNF) in NF1 | Phase 2a: dose-dependent MEK inhibition with 47% reduction in p-ERK at 0.5%; 20% of treated cNFs had >=50% volume reduction vs 6% with vehicle after 28 days (pqac-00000000) | Not FDA approved in cited evidence | No local or systemic toxicities observed during short treatment period; systemic levels remained <1 ng/mL; durability still under study (pqac-00000000) |
| Imatinib | Tyrosine kinase inhibitor | Investigational treatment for plexiform neurofibromas | Reported median tumor volume reduction of 26.5% in review summaries; explored before MEK inhibitors became standard (pqac-00000026, pqac-00000028) | Not FDA approved specifically for neurofibroma / NF1-PN in cited evidence | Limited efficacy compared with MEK inhibitors; off-target toxicities typical of TKIs; not current standard of care (pqac-00000026) |
| Surgical resection / debulking | Operative removal of tumor; potentially curative if complete excision feasible | Symptomatic cutaneous or plexiform neurofibromas causing pain, neurologic deficit, disfigurement, airway compromise, or orthopedic complications | Remains standard and only potentially curative local option, but many PN are unresectable; regrowth after surgery ranges ~20-68% depending on extent of resection (pqac-00000022, pqac-00000024) | Standard clinical practice, not an FDA-regulated drug approval question | Risks include bleeding, neurologic injury, incomplete resection, recurrence/regrowth, and anatomic inaccessibility (pqac-00000022, pqac-00000024, pqac-00000026) |
| Gene therapy approaches | Experimental gene restoration / editing strategies, including AAV-based NF1 restoration concepts | Future disease-modifying therapy for NF1-associated neurofibromas and related tumors | Preclinical/early translational only in gathered evidence; recent reviews highlight AAV-based gene therapy, gene-targeted approaches, and humanized/iPSC models to enable testing (pqac-00000009, pqac-00000057) | No FDA-approved gene therapy for neurofibroma in cited evidence | Major limitations include delivery of the large NF1 gene, durability, tumor heterogeneity, and need for robust preclinical validation (pqac-00000009, pqac-00000057) |


*Table: This table summarizes current and emerging treatments for neurofibroma, especially NF1-associated plexiform and cutaneous neurofibromas. It highlights mechanisms, indications, response rates, approval status, and key safety considerations to support knowledge base curation and comparative review.*